MARKET

INCY

INCY

Incyte Corp
NASDAQ
106.21
+0.97
+0.92%
After Hours: 106.88 +0.67 +0.63% 19:35 01/16 EST
OPEN
105.55
PREV CLOSE
105.24
HIGH
108.58
LOW
104.83
VOLUME
1.70M
TURNOVER
--
52 WEEK HIGH
112.29
52 WEEK LOW
53.56
MARKET CAP
20.85B
P/E (TTM)
17.96
1D
5D
1M
3M
1Y
5Y
1D
Assessing Incyte (INCY) Valuation After Strong 1 Year Returns And Recent Share Price Momentum
Simply Wall St · 7h ago
Incyte: Buy For The Turnaround, Stay For The Pipeline
Seeking Alpha · 1d ago
XPH: Healthcare Dashboard For January
Seeking Alpha · 1d ago
Incyte Advances Microneedle Skin Sampling Platform With Completion of Observational Study in Atopic Dermatitis
TipRanks · 1d ago
Incyte's Pipeline Potential Signals Massive Upside For Investors
Seeking Alpha · 1d ago
Steven Cress' Top 10 Stocks For 2026
Seeking Alpha · 2d ago
Incyte: Transitioning Beyond Jakafi With a Promising but Unproven Late-Stage Pipeline Warrants Hold Rating
TipRanks · 2d ago
Grail and Indivior PLC come out on top in Healthcare quant picks ahead of Q4 earnings
Seeking Alpha · 3d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.